SynthesisImmunity, inflammation and disease2026
RSV-Pre-F Vaccination During Pregnancy and Neonatal Outcomes-A Systematic Review and Meta-Analysis.
Synthesis in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesRespiratory syncytial virus (RSV) is a major cause of infant morbidity and mortality worldwide. Recent preventive strategies include maternal vaccination and monoclonal antibodies. However, maternal RSV vaccination has raised safety concerns due to possible associations with preterm birth. This systematic review and meta-analysis evaluated whether maternal RSV vaccination increases the risk of preterm birth and neonatal intensive care unit (NICU) admission.
methodsA systematic search of PubMed, Scopus, and Web of Science was conducted on August 1st, 2025. We used the following keywords in the search: RSV, vaccine, preterm, and neonate. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing currently approved RSV-PreF vaccines in pregnancy and reporting preterm birth (< 37 weeks) or NICU admission. Data extraction and risk of bias assessments (RoB 2.0, ROBINS-I) were performed independently by two reviewers. Meta-analyses were conducted using random-effects models with risk ratios (RRs) as effect measures, and the certainty of evidence was graded using the GRADE framework.
resultsSeven studies met inclusion criteria: three RCTs (n = 12,833 births) and four observational studies (n = 4245 births). In RCTs, RSV vaccination was associated with an increased risk of preterm birth (RR 1.26, 95% CI 1.08-1.46), while observational studies showed no association (RR 0.78, 95% CI 0.46-1.32). Pooled analysis revealed no overall association (RR 0.96, 95% CI 0.68-1.38). NICU admission risk was not significantly affected (RR 0.74, 95% CI 0.34-1.61). Certainty of evidence was rated low to very low.
conclusionsThis meta-analysis found no overall evidence linking maternal RSV vaccination to preterm birth, though RCT subgroup findings suggest a potential increased risk. Continued surveillance and long-term safety monitoring are essential as global implementation expands.
trial registrationOpen Science Framework (https://osf.io/3tfkn/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.